Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • BI 860585 - Neoplasms
    Clinical Study Number 1325.1
    Study Indication Neoplasms
    Product BI 860585
    Generic Name BI 860585
    Lab Code BI 860585
    Clinical Phase I
    Study Title

    An open-label, Phase I, dose-finding study of BI 860585 administered orally in a continuous dosing schedule as a single agent and in combination with exemestane or with paclitaxel in patients with various advanced and/or metastatic solid tumours

    Study Document
    Trial synopsis 1325.1 english
    Lay summary 1325.1 english